Uploaded May 2026 | Updated November 2026, 3 days ago
Childhood cancers are mostly curable thanks to breakthroughs in paediatric medicine. But, behind the headlines, complex machinery and logistics are required to generate the evidence to support new treatments, but limited by the practical challenge of generating credible, robust evidence.
The University of Birmingham is tackling this challenge through Glo-BNHL, an international platform trial for children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. Amos Burke, Professor of Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham Women’s and Children’s Hospital, directs the Cancer Research UK Clinical Trials Unit (CRCTU) and is Chief Investigator of the Glo-BNHL project.
Find out more about our Paediatric Oncology research: birmingham.ac.uk/news/2026/a-blueprint-for-faster-fairer-drug-development-in-rare-childhood-cancers
Childhood cancers are mostly curable thanks to breakthroughs in paediatric medicine. But, behind the headlines, complex machinery and logistics are required to generate the evidence to support new treatments, but limited by the practical challenge of generating credible, robust evidence.
The University of Birmingham is tackling this challenge through Glo-BNHL, an international platform trial for children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. Amos Burke, Professor of Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham Women’s and Children’s Hospital, directs the Cancer Research UK Clinical Trials Unit (CRCTU) and is Chief Investigator of the Glo-BNHL project.
Find out more about our Paediatric Oncology research: birmingham.ac.uk/news/2026/a-blueprint-for-faster-fairer-drug-development-in-rare-childhood-cancers










